Safety and Effectiveness of Omega 3-Fatty Acids, EPA Versus DHA, for the Treatment of Major Depression

Completed · Phase 3 · Has a placebo group

Conditions studied: Major Depressive Disorder

In brief

This study examines the difference in the effectiveness of two natural compounds, eicosapentanoic (EPA) and docosahexanoic (DHA)omega-3 fatty acids, in treating major depressive disorder. Both types of omega-3 fatty acids are commonly found in fish oils. It is believed that a deficiency in these omega-3 fatty acids may lead to the development of major depression.

Key facts

Study ID

NCT00361374

Run by

Massachusetts General Hospital

People needed

196

Starts

2006-07-01

Expected to finish

2013-03-01

Last updated by the study team

2014-07-18

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Men or women aged 18-80 years old.
• Must meet criteria for current Major Depressive Disorder.

You may not qualify if…

• Serious or unstable medical illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic, or hematologic disease
• History of seizure disorder.
• Substance use disorders, including alcohol, active within the last six months (past history is OK).
• History of multiple adverse drug reactions or allergy to the study drugs.

Where it is running

• Depression Clinical Research Program, Massachusetts General Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.